Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome

Trial Profile

Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Celiprolol (Primary)
  • Indications Ehlers-Danlos syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2017 According to an Acer Therapeutics media release, company plans to file an NDA for celiprolol (EDSIVO) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the first half of 2018, and data from this trial, which was verified by an Acer-sponsored retrospective source will be utilised to support the application.
    • 25 Sep 2017 According to an Acer Therapeutics Media Release, data were published on October 30, 2010, in The Lancet.
    • 25 Sep 2017 Results presented in an Acer Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top